{"filing":{"accession_number":"0001437749-26-022859","cik":"0001131343","ticker":"PRNAF","company_name":"ALTERITY THERAPEUTICS LTD","form":"6-K","filing_date":"2026-07-07","report_date":null,"primary_document":"athe20260707_6k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1131343/000143774926022859/athe20260707_6k.htm"},"events":[{"id":16292,"run_id":14542,"accession_number":"0001437749-26-022859","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"This press release announces receipt of official FDA End-of-Phase 2 meeting minutes confirming a registrational pathway for ATH434 in Multiple System Atrophy, including FDA agreement on Phase 3 trial design and the possibility of approval based on a single pivotal trial plus confirmatory evidence. This is a material regulatory and clinical development milestone that advances the company's lead drug candidate toward potential NDA filing, but it is not a discrete event type in the taxonomy (not M\u0026A, not an earnings release, not an executive change, not a restatement or going-concern issue). It represents a significant operational/strategic advancement in the drug development program that would affect a reasonable investor's assessment of the company's prospects.","company_name":"ALTERITY THERAPEUTICS LTD","ticker":"PRNAF","filing_date":"2026-07-07","form":"6-K","submitted_at":null,"items":[{"id":14350,"accession_number":"0001437749-26-022859","item_number":"EX-99.1","item_title":"ex_985272.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"This press release announces receipt of official FDA End-of-Phase 2 meeting minutes confirming a registrational pathway for ATH434 in Multiple System Atrophy, including FDA agreement on Phase 3 trial design and the possibility of approval based on a single pivotal trial plus confirmatory evidence. This is a material regulatory and clinical development milestone that advances the company's lead drug candidate toward potential NDA filing, but it is not a discrete event type in the taxonomy (not M\u0026A, not an earnings release, not an executive change, not a restatement or going-concern issue). It represents a significant operational/strategic advancement in the drug development program that would affect a reasonable investor's assessment of the company's prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-07T19:07:50.765481+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":14350,"accession_number":"0001437749-26-022859","item_number":"EX-99.1","item_title":"ex_985272.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"This press release announces receipt of official FDA End-of-Phase 2 meeting minutes confirming a registrational pathway for ATH434 in Multiple System Atrophy, including FDA agreement on Phase 3 trial design and the possibility of approval based on a single pivotal trial plus confirmatory evidence. This is a material regulatory and clinical development milestone that advances the company's lead drug candidate toward potential NDA filing, but it is not a discrete event type in the taxonomy (not M\u0026A, not an earnings release, not an executive change, not a restatement or going-concern issue). It represents a significant operational/strategic advancement in the drug development program that would affect a reasonable investor's assessment of the company's prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-07T19:07:50.765481+00:00","company_name":"ALTERITY THERAPEUTICS LTD","ticker":"PRNAF","filing_date":"2026-07-07"}]}